Description
DetellaDx is developing screening and diagnostic solutions for early detection of ovarian cancer at Stage I when it is still a treatable disease. They are a UW spin out. They leverage both biology and technology to reach very high levels of sensitivity and specificity needed for success. Their primary target population is women with genetic predisposition for ovarian cancer whose chances of developing this cancer can be up to 50%.
Team Members
Scott Kennedy
Co-Founder & Chief Scientific Officer
Kellie Bickel
Co-Founder & Chief Business Officer
Elena Cant
CEO & Co-Founder